GoodRx Receives Notice of Non-Compliance From Nasdaq

November 23, 2026

SANTA MONICA, Calif.--(BUSINESS WIRE)--Nov. 23, 2026-- On November 17, 2026, GoodRx Holdings, Inc. (Nasdaq: GDRX) (the "Company") received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission.

The Notice provides that the Company has until January 19, 2027 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts such plan, it may grant an extension of up to 180 calendar days, or until May 17, 2027, to regain compliance. The Notice has no immediate effect on the listing of the Company's Class A common stock on Nasdaq.

While the Company can provide no assurances as to timing, the Company continues to work diligently to complete its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026. The Company intends to file it as promptly as possible in order to regain compliance with the Nasdaq Listing Rule prior to January 19, 2027, which would eliminate the need for the Company to submit to Nasdaq a formal plan to regain compliance.

About GoodRx

GoodRx is the trusted platform for prescription access and affordability. The company helps consumers navigate care, cost, and fulfillment so they can start and stay on treatment, while enabling partners to deliver self-pay pricing, affordability programs, and pharmacy access at scale. With a trusted brand, nationwide pharmacy network, and more than 280 million annual site visits, GoodRx reaches consumers at the moments when cost and access are shaping healthcare decisions. Since 2011, GoodRx has helped Americans save over $100 billion on medications.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

Forward Looking Statements

All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company's intention to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 prior to January 19, 2027 and its ability to regain compliance with the Nasdaq Listing Rules. These statements represent current expectations and beliefs and no assurance can be given that the results described in such statements will be achieved. Such statements involve known and unknown risks, uncertainties, and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to the restatement of the Company's financial statements for quarterly periods ended March 31, 2026 and June 30, 2026, the sufficiency of the Company's internal control over financial reporting and impacts from anticipated related material weakness as well as additional risks, uncertainties and other factors, including those described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, once filed, and in its other filings with the Securities and Exchange Commission. No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261123103304/en/

Investor Contact
GoodRx
Aubrey Reynolds
ir@goodrx.com

Press Contact
GoodRx
Lauren Casparis
lcasparis@goodrx.com

Source: GoodRx